Hemodez-H (Haemodes-N)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePotassium Chloride + Calcium Chloride + Magnesium Chloride + Sodium Hydrocarbonate + Sodium Chloride + Povidone-8 Thousand.Potassium chloride + Calcium chloride + Magnesium chloride + Sodium bicarbonate + Sodium chloride +Povidone-8 thousand.
Similar drugsTo uncover
  • Hemodez-8000
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Hemodez-H
    solution d / infusion 
    MAKSFARM, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    MOSFARM, LLC    
  • Hemodez-H
    solution d / infusion 
    ESKOM NPK, OAO     Russia
  • Hemodez-H
    solution d / infusion 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    Kursk Biofactory - BIOK, FKP     Russia
  • Hemodez-H
    solution d / infusion 
    RESTER, CJSC     Russia
  • Hemodez-H
    solution d / infusion 
    ELFARMI, LTD.     Russia
  • Hemodez-H
    solution d / infusion 
    PHARMSTANDART-UFIM VITAMIN FACTORY, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    DALHIMFARM, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    ATOLL, LLC     Russia
  • Krasgemodez 8000
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Krasgemodez 8000
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Neohemodes
    solution in / in 
    SYNTHESIS, OJSC     Russia
  • Neohemodes
    solution inwards 
    FIRM MEDPOLIMER, JSC     Russia
    • Dosage form: & nbspsolution for infusions
    Composition:

    Povidone (Low molecular weight polyvinylpyrrolidone (8000 ± 2000)

    -60 g

    Sodium chloride

    - 5.5 g

    Potassium chloride

    - 0.42 g

    Calcium chloride 6-water (in terms of anhydrous)

    - 0.5 g

    Magnesium chloride 6-water (in terms of anhydrous)

    0.005 g

    Sodium bicarbonate

    - 0.23 g

    Water for injections

    up to 1 liter

    Description:

    Transparent liquid from colorless to yellow.

    Pharmacotherapeutic group:Detoxifying agent
    ATX: & nbsp

    B.05.A.A   Blood plasma preparations and plasma-substituting drugs

    Pharmacodynamics:

    The action of Hemodeza-H is due to the ability of low molecular weight polyvinylpyrrolidone to bind toxins circulating in the blood and quickly remove them from the body. The most fully binds toxins circulating in the blood of patients with dysentery, salmonella, food intoxication. At a burn disease at different periods of the disease, different toxins are produced. Those of them that are formed in the first 4-5 days of the disease are quite fully inactivated; toxins formed at a later date are much less neutralized.

    Toxins formed in the body of patients with acute radiation sickness do not bind, although it is possible to accelerate their excretion from the body.

    The drug contributes to the elimination of stasis of erythrocytes in capillaries, developing with intoxication of any origin, which leads to an improvement in microcirculation.It increases renal blood flow, increases glomerular filtration and increases diuresis. The drug is non-toxic, does not have antigenic and pyrogenic properties. The decrease in the molecular weight of the polymer accelerates the excretion of it by the kidneys from the body and improves the detoxification properties of the preparation.
    Pharmacokinetics:

    Metabolic transformations in the body are not exposeis used. Quickly excreted by the kidneys, within 4 hours 80% is output, and after 12 - 24 hours - completely.

    Indications:

    Shock (post-traumatic, postoperative, burn, hemorrhagic), intoxication (toxic diseases of the gastrointestinal tract: dysentery, dyspepsia, salmonellosis); as a means of detoxification in the postoperative period with peritonitis; liver disease, accompanied by the development of liver failure; intestinal obstruction; thyrotoxicosis; burn disease; acute radiation sickness; sepsis; pneumonia; acute phase of myocardial infarction; hemolytic disease of newborns; intrauterine infection and toxemia of newborns; Toxicosis of pregnant women.

    Contraindications:

    Hypersensitivity to the drug, intracranial hypertension, hemorrhagic stroke,condition after traumatic brain injury, cardiovascular insufficiency IIb - III degree, respiratory failure, severe allergic reactions, thromboembolism, oliguria, anuria, acute nephritis, bronchial asthma, phlebothrombosis.

    Carefully:Not described.
    Pregnancy and lactation:Not described.
    Dosing and Administration:

    Hemodez-H is injected through a system with a filter intravenously drip. The dose of the drug, depending on the age of the patient and the intensity of intoxication is different.

    For infants - 5-10 ml / kg. The maximum single dose for them is 70 ml; for children from 2 to 5 years - 100 ml; from 5 to 10 years - 150 ml; from 10 to 15 years - 200 ml.

    For adults, the single maximum dose is 400 ml. The therapeutic effect is manifested at a dose of 1.5 ml / kg.

    Patients with large focal myocardial infarction received on the 1st day of the disease, Hemodez-H is administered in a dose of 200 ml.

    In some cases (prolonged pain, severe arrhythmias, cardiogenic shock, or a combination of these complications with concomitant diabetes), the drug is given twice a second at the same dose (200 ml). Before administration, the solution is warmed to body temperature.

    Side effects:

    With the slow introduction of Haemodesum-H, complications do not usually arise. Introduction with increased speed can cause a decrease in blood pressure, tachycardia, difficulty breathing and require the introduction of vasoconstrictor and cardiac agents, calcium chloride. Individual patients may experience allergic reactions, up to the development of anaphylactic shock. In these cases, you should immediately stop the infusion, conduct symptomatic therapy (introduce antihistamines, cardiotonic drugs, glucocorticoids, vasopressive drugs).

    Overdose:

    In case of an overdose, the drug should be withdrawn and symptomatic therapy should be performed.

    Interaction:Not described.
    Special instructions:With extensive burns combined with the introduction of plasma, albumin, gamma globulin. Before starting the infusion, the doctor must check the expiry date of the package. The drug should be clear, free of sediment, sediment and mold. 11Check the integrity and integrity of the packaging. The results of a visual examination are recorded in the history of the disease.
    Effect on the ability to drive transp. cf. and fur:Not described.
    Form release / dosage:

    Solution for infusions of 100, 200, 400 ml.

    Packaging:In glass bottles for blood, transfusion and infusion preparations with a capacity of 100, 250 and 450 ml. Each bottle, along with the instructions for use, is placed in a cardboard box.

    For hospitals: bottles without bundles are placed in a cardboard box along with instructions for use or in wrappers from shrink film, which are then placed in a cardboard box.

    Storage conditions:

    In a dry place at a temperature not higher than +25 С. Keep out of the reach of children. Freezing the drug (provided that the packaging is kept sealed) is not a contraindication to its use. Non-wetting of the inner surface of bottles is not a contraindication to the use of the drug.

    Shelf life:

    2 years. Do not use after the date shown on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-008575/08
    Date of registration:29.10.2008
    Expiration Date:Unlimited
    The owner of the registration certificate:MAKSFARM, OJSC MAKSFARM, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp21.03.2017
    Illustrated instructions
      Instructions
      Up